| Literature DB >> 23036642 |
Sasan Partovi, Anja-Carina Schulte, Markus Aschwanden, Daniel Staub, Daniela Benz, Stephan Imfeld, Björn Jacobi, Pavel Broz, Kurt A Jäger, Martin Takes, Rolf W Huegli, Deniz Bilecen, Ulrich A Walker.
Abstract
INTRODUCTION: Muscle symptoms in systemic sclerosis (SSc) may originate from altered skeletal muscle microcirculation, which can be investigated by means of blood oxygenation level dependent (BOLD) magnetic resonance imaging (MRI).Entities:
Mesh:
Substances:
Year: 2012 PMID: 23036642 PMCID: PMC3580521 DOI: 10.1186/ar4047
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Figure 1Imaging setup of the ischemia/reactive hyperemia paradigm conducted with a conventional leg sphygmomanometer wrapped around the middle of the thigh and flexible array coils. To prevent compression of the calf muscles the lower leg is supported at knee and foot level.
Figure 2T1 images and T2* maps of the upper left calf region from a healthy volunteer and a patient with systemic sclerosis (SSc). T1 images are shown on the left and T2* maps on the right. (A) Healthy volunteer. (B) SSc patient. T1 images were correlated for anatomical reference with the respective T2* maps.
Figure 3Key parameters of a typical blood oxygenation level-dependent (BOLD) T2* signal time course in a healthy volunteer. T2* is a magnetic resonance imaging signal.
Clinical characteristics of eleven patients with systemic sclerosis undergoing blood oxygenation level-dependent MRI of the calf muscles
| Characteristic | Value |
|---|---|
| SSc duration by first non-Raynaud's symptom, mean (years) | 5.4, SD 5.0 |
| SSc duration by onset of Raynaud's phenomenon, mean (years) | 6.8, SD 6.2 |
| Diffuse cutaneous SSc, n | 3 |
| Limited cutaneous SSc, n | 5 |
| Other SSc, n | 3 |
| Modified Rodnan skin score, median | 5, range 1-26 |
| Antinuclear autoantibody positive, n | 11 |
| Anti-centromere autoantibodies positive, n | 3 |
| Anti-topoisomerase autoantibodies positive, n | 5 |
| PM-Scl autoantibodies positive, n | 1 |
| Erythrocyte sedimentation rate, mean (mm) | 14, SD 12 |
| Serum creatine kinase elevation, n | 2 |
| Muscle atrophy, n | 1 |
| Muscle weakness on manual muscle testing, n | 1 |
| Six-minute walk test distance, mean (meters) | 449, SD 68 |
| Cardiopulmonary function | |
| Systolic blood pressure, mean (mmHg) | 127, SD 17 |
| Diastolic blood pressure, mean (mmHg) | 78, SD 11 |
| Systolic pulmonary arterial pressure by echocardiography, mean (mmHg) | 23.7, SD 4.4 |
| Forced vital capacity, mean % of normal | 91.4, SD 18.6 |
| Diffusing capacity of the lung for carbon monoxide, mean % of normal | 73.1, SD 26.3 |
| Patients on prednisone, n | 5 |
| Patients on methotrexate, azathioprine, mycophenolate, or cyclophosphamide, n | 7 |
SSc, systemic sclerosis; BOLD, blood oxygenation level-dependent; MRI, magnetic resonance imaging; n, number of patients.
Figure 4Muscle blood oxygenation level-dependent (BOLD) time courses in patients with scleroderma and healthy controls. Time courses for patients with scleroderma are shown in red and for healthy controls in blue in (A) the soleus and (B) the gastrocnemius muscle. (C) Mean time courses over both muscle groups. T2* is a magnetic resonance imaging signal.
Calf muscle blood oxygenation level-dependent (BOLD) key parameters of all eleven patients with systemic sclerosis (SSc) and twelve volunteers
| Volunteers | SSc patients | ||
|---|---|---|---|
| Soleus, mean (SD) | -10.3 (4.0) | -13.4 (6.9) | 0.20 |
| Gastrocnemius, mean (SD) | -8.0 (4.6) | -18.0 (9.9) | 0.005 |
| Both, mean (SD) | -9.1 (3.5) | -15.0 (7.3) | 0.021 |
| Soleus, median (IQR) | 26.4 (20.0, 30.6) | 15.7 (6.5, 21.9) | < 0.007 |
| Gastrocnemius, median (IQR) | 17.2 (9.4, 32.0) | 4.3 (0.1, 6.4) | 0.002 |
| Both, median (IQR) | 20.1 (17.0, 29.6) | 9.2 (4.4, 17.5) | 0.007 |
| Soleus, median (IQR) | 32.0 (30.0, 35.5) | 38.0 (34.0, 54.0) | 0.037 |
| Gastrocnemius, median (IQR) | 34.0 (27.5, 37.3) | 42.0 (38.0, 50.0) | 0.002 |
| Both, median (IQR) | 33.5 (29.5, 36.5) | 39.0 (35.0, 56.0) | 0.026 |
| Soleus, mean (SD) | -17.9 (4.9) | -10.3 (5.7) | 0.002 |
| Gastrocnemius, mean (SD) | -14.7 (6.1) | -6.6 (7.0) | < 0.001 |
| Both, mean (SD) | -16.5 (4.6) | -7.3 (4.9) | < 0.001 |
| Soleus, mean (SD) | -14.8 (3.3) | -6.2 (4.4) | < 0.001 |
| Gastrocnemius, mean (SD) | -11.7 (5.6) | -4.5 (4.9) | 0.004 |
| Both, mean (SD) | -13.7 (4.1) | -4.6 (3.6) | <0.001 |
| Soleus mean (SD) | -0.3 (3.9) | 1.0 (4.4) | 0.45 |
| Gastrocnemius, mean (SD) | 0.8 ± 3.3 | -0.3 (3.4) | 0.41 |
| Both, mean (SD) | -0.7 (4.2) | -0.3 (2.7) | 0.77 |
Parameters were obtained for the soleus and gastrocnemius muscle. Normally distributed parameters are provided as means with SD, non-normally distributed parameters are provided as medians with interquartile ranges (IQR). T2*min, ischemic minimum of T2*; T2*max, T2* peak value during reactive hyperemia; TTP, time to peak; DS, declining slope after hyperemia peaking; EV, T2* end value. T2*min, T2*max and EV were calculated relative to baseline. DS60s and DS120s represent T2*declining slopes between T2*max and 60 s or 120 s afterwards.